Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FRED ELIAS GHALI

Allopathic & Osteopathic Physicians Dermatology Pediatric Dermatology

NPI
1639286339
CMS profile
255273
Location
GRAPEVINE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$37,073.76

92 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FRED ELIAS GHALI

NPI 1639286339 · CMS profile ID 255273

Allopathic & Osteopathic Physicians / Dermatology / Pediatric Dermatology

GRAPEVINE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639286339?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FRED ELIAS GHALI, NPI 1639286339, CMS profile ID 255273. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639286339?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). FRED ELIAS GHALI, NPI 1639286339, CMS profile ID 255273. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639286339?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
FRED ELIAS GHALI, NPI 1639286339, CMS profile ID 255273, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–92 of 92 matching records. This page contains 42 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1639286339?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

92 matching records · $37,073.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 92 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–92 of 92.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $1,405.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580423 CMS
Regeneron Healthcare Solutions, Inc. $1,686.0007/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580425 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $22.8807/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851881575 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $2,520.0007/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814974589 CMS
Regeneron Healthcare Solutions, Inc. $18.7607/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580419 CMS
GENZYME CORPORATION $112.3207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493629 CMS
GENZYME CORPORATION $3,372.0007/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493631 CMS
GENZYME CORPORATION $3,372.0006/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493607 CMS
GENZYME CORPORATION $6.7206/25/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493609 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $14.0206/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849552711 CMS
GENZYME CORPORATION $18.4206/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493603 CMS
GENZYME CORPORATION $10.4206/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493599 CMS
Lilly USA, LLC $7.6806/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937107173 CMS
GENZYME CORPORATION $22.3006/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493601 CMS
Regeneron Healthcare Solutions, Inc. $18.3406/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580417 CMS
AbbVie Inc. $24.8806/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794582375 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $3,600.0005/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814974581 CMS
Regeneron Healthcare Solutions, Inc. $15.5605/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580415 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $22.6805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851881571 CMS
AbbVie Inc. $9.1005/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794582371 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $22.7405/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849552707 CMS
AbbVie Inc. $5.6305/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794582367 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.3104/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851881573 CMS
Galderma Laboratories, L.P. $19.8204/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855275875 CMS
Regeneron Healthcare Solutions, Inc. $35.8204/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580413 CMS
AbbVie Inc. $20.6204/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794582363 CMS
Lilly USA, LLC $7.7103/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937109819 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.9403/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851881569 CMS
AbbVie Inc. $6.9103/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794582359 CMS
Regeneron Healthcare Solutions, Inc. $26.4903/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580411 CMS
GENZYME CORPORATION $23.0203/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493581 CMS
Regeneron Healthcare Solutions, Inc. $31.6103/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580409 CMS
GENZYME CORPORATION $1,967.0003/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493587 CMS
Regeneron Healthcare Solutions, Inc. $17.8002/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580407 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $17.1302/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849552705 CMS
Galderma Laboratories, L.P. $13.8002/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855275873 CMS
Galderma Laboratories, L.P. $16.2902/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855275871 CMS
Lilly USA, LLC $23.6601/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937111071 CMS
Regeneron Healthcare Solutions, Inc. $30.0801/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580405 CMS
GENZYME CORPORATION $18.1001/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843493573 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $23.2001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851881567 CMS
Almirall LLC $22.9801/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819686977 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $116,866.79 171
PY2020 $95,872.36 147
PY2021 $37,073.76 92
PY2022 $67,942.30 214
PY2023 $81,061.45 242
PY2024 $94,279.91 227
PY2025 $130,856.78 297

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $111,075.30 15
PY2024 Principal investigator $30,816.85 34
PY2023 Recipient $2,700.00 1
PY2023 Principal investigator $102,108.81 62
PY2022 Principal investigator $8,142.64 9
PY2021 Recipient $3,540.05 2
PY2021 Principal investigator $1,820.00 5
PY2020 Principal investigator $25,436.00 34
PY2019 Recipient $700.00 2
PY2019 Principal investigator $4,423.00 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $4,469.00 12/19/2025 Non-covered Recipient Entity
STAT MEDICAL SERVICES
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240596958
Principal investigator 1 Ferring Pharmaceuticals AS $3,550.00 11/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242061286
Principal investigator 1 Incyte Corporation $1,933.00 10/29/2025 Non-covered Recipient Entity
STAT MEDICAL SERVICES
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240596954
Principal investigator 1 Ferring Pharmaceuticals AS $10,581.30 10/23/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242061233
Principal investigator 1 Incyte Corporation $2,504.00 09/23/2025 Non-covered Recipient Entity
STAT MEDICAL SERVICES
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240596950
Principal investigator 1 Ferring Pharmaceuticals AS $1,800.00 09/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060918
Principal investigator 1 Ferring Pharmaceuticals AS $1,200.00 09/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060922
Principal investigator 1 Incyte Corporation $5,024.00 08/26/2025 Non-covered Recipient Entity
STAT MEDICAL SERVICES
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240596942
Principal investigator 1 Incyte Corporation $2,259.00 08/14/2025 Non-covered Recipient Entity
STAT MEDICAL SERVICES
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240596946
Principal investigator 1 Ferring Pharmaceuticals AS $5,900.00 08/04/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060833
Principal investigator 1 Ferring Pharmaceuticals AS $1,450.00 07/25/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060789
Principal investigator 1 Incyte Corporation $7,331.00 06/24/2025 Non-covered Recipient Entity
STAT MEDICAL SERVICES
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240596938
Principal investigator 1 Ferring Pharmaceuticals AS $30,000.00 06/05/2025 Non-covered Recipient Entity
YALE UNIVERSITY
A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) No dispute reported 06/30/2026 1242060484
Principal investigator 1 Eli Lilly and Company $21,074.00 02/05/2025 Non-covered Recipient Entity
SUNRISE MEDICAL RESEARCH INC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187892498
Principal investigator 1 Incyte Corporation $12,000.00 01/29/2025 Non-covered Recipient Entity
ACRC TRIALS
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240498378